⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

August 1, 2024Open Access

Supplementary Figure S9 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity

Naveen K. Mehta Kavya Rakhra Kristan Meetze Bochong Li Noor Momin Jason Y.H. Chang K. Dane Wittrup Patrick A. Baeuerle Jennifer S. Michaelson

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Immunophenotyping of peripheral blood

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mehta et al. (2024) studied this question.

synapsesocial.com/papers/68e5e0ecb6db64358757565c https://doi.org/10.1158/2326-6066.26422403.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S9 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity2024
2Supplementary Figure S13 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity2024
3Supplementary Figure S13 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity2024
4Supplementary Figure S8 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity2024
5Supplementary Figure S8 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity2024